Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 6:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Microneedle Clear all
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Assessing the Feasibility of Multi-modal Biosensing for Monitoring Mobility and Cognition in Older Adults

NCT07217951
View directory record Official record
Conditions
Chronic Stress, Systemic Inflammation, Mobility and Independence
Interventions
Eutectogel Sensors and Microneedle Patches
Device
Lead sponsor
Tufts University
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Racial/Ethnic Differences in Microneedle Response

NCT03332628
View directory record Official record
Conditions
Healthy
Interventions
Microneedle patch
Device
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 50 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 14, 2021 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis

NCT01789320
View directory record Official record
Conditions
Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis, Noninfectious Uveitis
Interventions
triamcinolone acetonide (Triesence®)
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Chicago, Illinois • Omaha, Nebraska • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Phase 2 Interventional

Phase 2 Study Evaluating the Safety and Efficacy of Microneedle-mediated Delivery of Doxorubicin (D-MNA) in Patients With Nodular Basal Cell Carcinoma.

NCT06608238
View directory record Official record
Conditions
Nodular Basal Cell Carcinoma
Interventions
D-MNA 200µg, D-MNA 100µg, Microneedle Array Alone
Drug · Other
Lead sponsor
SkinJect, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Fresno, California • San Diego, California • Naperville, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Visualizing Dermal Micropores With OCT

NCT04867733
View directory record Official record
Conditions
Healthy
Interventions
Micropatch (microneedle patch)
Other
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 45 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 27, 2024 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Phase 2 Interventional Results available

Intradermal Versus Intramuscular Polio Vaccine Booster in HIV-Infected Subjects

NCT01686503
View directory record Official record
Conditions
Polio Immunity
Interventions
IPOL (Sanofi Pasteur) inactivated polio vaccine booster dose
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 90 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 4, 2015 · Synced Sep 17, 2026, 6:19 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Pharmacokinetics of Transdermal Metronidazole

NCT05929794
View directory record Official record
Conditions
Healthy
Interventions
Metronidazole 0.75% Topical Gel, Metronidazole 0.75% Topical Cream, Transdermal water loss measurement, Electrical Resistance, Skin color measurement, Micropatch application
Drug · Diagnostic Test · Other
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Lutronic Infini and LaseMD Systems in Combination Treatment

NCT03409965
View directory record Official record
Conditions
Face and Neck Wrinkles, Texture, Pigmentation
Interventions
Lutronic Infini System, Lutronic LaseMD System
Device
Lead sponsor
CynosureLutronic
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Vista, California • Santa Rosa Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Phase 2 Interventional Results available

Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema

NCT03126786
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
IVT aflibercept, Sham SC, SC CLS-TA
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
29
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 17, 2026, 6:19 AM EDT
Recruiting Phase 1 Interventional

Safety of MOON101 for the Treatment of Peanut Allergy

NCT07580898
View directory record Official record
Conditions
Peanut Allergy
Interventions
Dose A, Dose B, Dose C, Dose D, Dose E, Placebo
Combination Product
Lead sponsor
Moonlight Therapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Little Rock, Arkansas • Atlanta, Georgia • Overland Park, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine

NCT02745392
View directory record Official record
Conditions
Acute Migraine
Interventions
ZP-Zolmitriptan, Placebo
Drug
Lead sponsor
Zosano Pharma Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
36
States / cities
Glendale, Arizona • Carlsbad, California • Huntington Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Phase 1 Interventional

A Study to Determine the Patient Preference Between Zosano Pharma Parathyroid Hormone (ZP-PTH) Patch and Forteo Pen

NCT02478879
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
ZP-PTH, FORTEO
Drug
Lead sponsor
Zosano Pharma Corporation
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 22, 2016 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Gentamicin for RDEB

NCT03012191
View directory record Official record
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
Gentamicin Sulfate
Drug
Lead sponsor
University of Southern California
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 17, 2026, 6:19 AM EDT
Recruiting Phase 1Phase 2 Interventional

Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)

NCT05377905
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma, Skin Cancers - Squamous Cell Carcinoma
Interventions
Microneedle Array Doxorubicin (MNA-D)
Drug
Lead sponsor
Falo, Louis, MD
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison of 1,550-nm Laser and Fractional Radiofrequency Microneedle for the Treatment of Acne Scars in Ethnic Skin

NCT03380845
View directory record Official record
Conditions
Acne Scars
Interventions
Fraxel Restore, Fractora
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Insulin Delivery Using Microneedles in Type 1 Diabetes

NCT00837512
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Microneedle, Subcutaneous insulin catheter
Device
Lead sponsor
Emory University
Other
Eligibility
8 Years to 18 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Microneedle Patch Study in Healthy Infants/Young Children

NCT03207763
View directory record Official record
Conditions
Vaccination, Skin Absorption
Interventions
Microneedle Formulation 1, Microneedle Formulation 2
Device
Lead sponsor
Emory University
Other
Eligibility
6 Weeks to 24 Months
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Sep 17, 2026, 6:19 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)

NCT04928222
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
Doxorubicin-containing MNA, Placebo-containing MNA
Combination Product · Drug
Lead sponsor
SkinJect, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
2
States / cities
West Palm Beach, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Phase 2 Interventional Results available

Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face

NCT02632110
View directory record Official record
Conditions
Actinic Keratosis
Interventions
ALA, Topical Solution Vehicle, IBL 10 mW, Microneedle lesion preparation, IBL 20 mW
Drug · Device · Procedure
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
8
States / cities
San Diego, California • Brandon, Florida • Arlington Heights, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Phase 3 Interventional Results available

Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis

NCT02595398
View directory record Official record
Conditions
Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
Interventions
4mg CLS-TA Suprachoriodal Injection, Sham Procedure
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Sep 17, 2026, 6:19 AM EDT
Not yet recruiting Not applicable Interventional

Feasibility Study of a Continuous Glucose-Ketone Monitoring Device in People With Type 1 Diabetes

NCT06977633
View directory record Official record
Conditions
Type 1 Diabetes (T1D)
Interventions
Temporary Insulin Suspension, Glucose and ketone sensor
Behavioral · Device
Lead sponsor
Mahla Poudineh
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intracutaneous Delivery of Varied Dose Volumes of Saline

NCT01767337
View directory record Official record
Conditions
Influenza
Interventions
FLUGEN 101.2 device
Device
Lead sponsor
FluGen Inc
Industry
Eligibility
18 Years to 49 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine

NCT03282227
View directory record Official record
Conditions
Migraine
Interventions
M207 Microneedle System
Drug
Lead sponsor
Zosano Pharma Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Sep 17, 2026, 6:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Inactivated Influenza Vaccine Delivered by Microneedle Patch or by Hypodermic Needle

NCT02438423
View directory record Official record
Conditions
Influenza
Interventions
Inactivated influenza vaccine, Placebo
Biological · Other
Lead sponsor
Mark Prausnitz
Other
Eligibility
18 Years to 49 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Sep 17, 2026, 6:19 AM EDT